ZA200503805B - Combination product of inhibitor of the Src familyof nonreceptor tyrosine kinases and gemcitabine - Google Patents

Combination product of inhibitor of the Src familyof nonreceptor tyrosine kinases and gemcitabine Download PDF

Info

Publication number
ZA200503805B
ZA200503805B ZA200503805A ZA200503805A ZA200503805B ZA 200503805 B ZA200503805 B ZA 200503805B ZA 200503805 A ZA200503805 A ZA 200503805A ZA 200503805 A ZA200503805 A ZA 200503805A ZA 200503805 B ZA200503805 B ZA 200503805B
Authority
ZA
South Africa
Prior art keywords
chloro
mixture
prophylaxis
composition
treatment
Prior art date
Application number
ZA200503805A
Other languages
English (en)
Inventor
Alan Barge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA200503805B publication Critical patent/ZA200503805B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Control And Other Processes For Unpacking Of Materials (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200503805A 2002-11-13 2005-05-11 Combination product of inhibitor of the Src familyof nonreceptor tyrosine kinases and gemcitabine ZA200503805B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0226434.9A GB0226434D0 (en) 2002-11-13 2002-11-13 Combination product

Publications (1)

Publication Number Publication Date
ZA200503805B true ZA200503805B (en) 2006-09-27

Family

ID=9947715

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200503805A ZA200503805B (en) 2002-11-13 2005-05-11 Combination product of inhibitor of the Src familyof nonreceptor tyrosine kinases and gemcitabine

Country Status (16)

Country Link
US (1) US20060142297A1 (OSRAM)
EP (1) EP1562612B1 (OSRAM)
JP (1) JP2006508953A (OSRAM)
KR (1) KR20050074573A (OSRAM)
CN (1) CN100467027C (OSRAM)
AT (1) ATE456370T1 (OSRAM)
AU (1) AU2003279456B2 (OSRAM)
BR (1) BR0316170A (OSRAM)
CA (1) CA2504666A1 (OSRAM)
DE (1) DE60331162D1 (OSRAM)
ES (1) ES2338109T3 (OSRAM)
GB (1) GB0226434D0 (OSRAM)
NO (1) NO20052312L (OSRAM)
NZ (1) NZ539514A (OSRAM)
WO (1) WO2004043472A1 (OSRAM)
ZA (1) ZA200503805B (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230302B1 (hu) 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
WO2004041829A1 (en) 2002-11-04 2004-05-21 Astrazeneca Ab Quinazoline derivatives as src tyrosine kinase inhibitors
ATE508747T1 (de) 2003-03-10 2011-05-15 Eisai R&D Man Co Ltd C-kit kinase-hemmer
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
CN100450998C (zh) 2003-11-11 2009-01-14 卫材R&D管理有限公司 脲衍生物的制备方法
GB0412074D0 (en) 2004-05-29 2004-06-30 Astrazeneca Ab Combination product
EP1797881B1 (en) 2004-09-17 2009-04-15 Eisai R&D Management Co., Ltd. Medicinal composition with improved stability and reduced gelation properties
GB0427697D0 (en) * 2004-12-17 2005-01-19 Astrazeneca Ab Chemical process
EP2281901B1 (en) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
EP2036557B1 (en) 2006-05-18 2015-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for thyroid cancer
CN101511793B (zh) 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
US20100048503A1 (en) 2007-01-19 2010-02-25 Eisai R & D Management Co., Ltd. Composition for treatment of pancreatic cancer
AU2008211952B2 (en) 2007-01-29 2012-07-19 Eisai R & D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
JP5638244B2 (ja) 2007-11-09 2014-12-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質と抗腫瘍性白金錯体との併用
MX2012014776A (es) 2010-06-25 2013-01-29 Eisai R&D Man Co Ltd Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados.
MX2013009931A (es) 2011-04-18 2013-10-01 Eisai R&D Man Co Ltd Agentes terapeuticos contra tumores.
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
TWI577671B (zh) * 2011-11-14 2017-04-11 Sunshine Lake Pharma Co Ltd Aminoquinazoline derivatives and salts thereof and methods of use thereof
WO2013152313A1 (en) 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
US9334239B2 (en) 2012-12-21 2016-05-10 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
US10517861B2 (en) 2013-05-14 2019-12-31 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN106660964B (zh) 2014-08-28 2021-09-03 卫材R&D管理有限公司 高纯度喹啉衍生物及其生产方法
PL3263106T3 (pl) 2015-02-25 2024-04-02 Eisai R&D Management Co., Ltd. Sposób tłumienia goryczy pochodnej chinoliny
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
US20170022576A1 (en) 2015-03-18 2017-01-26 The Regents Of The University Of California Compositions and methods for identifying anti-cancer, anti-metastatic and anti-stress agents
ES2886107T3 (es) 2015-06-16 2021-12-16 Prism Biolab Co Ltd Antineoplásico
AU2016309356B2 (en) 2015-08-20 2021-06-24 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
MX380144B (es) 2017-02-08 2025-03-12 Eisai R&D Man Co Ltd Composicion farmaceutica de tratamiento de tumores.
CA3061888A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
HUP0103640A3 (en) * 1998-09-25 2003-01-28 Warner Lambert Co Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
CA2383546A1 (en) * 1999-06-30 2001-01-04 William H. Parsons Src kinase inhibitor compounds
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
GB0101599D0 (en) * 2001-01-22 2001-03-07 Novartis Ag Organic compounds
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0412074D0 (en) * 2004-05-29 2004-06-30 Astrazeneca Ab Combination product

Also Published As

Publication number Publication date
AU2003279456B2 (en) 2007-05-17
WO2004043472A1 (en) 2004-05-27
DE60331162D1 (de) 2010-03-18
ES2338109T3 (es) 2010-05-04
GB0226434D0 (en) 2002-12-18
CN100467027C (zh) 2009-03-11
EP1562612A1 (en) 2005-08-17
BR0316170A (pt) 2005-09-27
NO20052312L (no) 2005-06-06
CA2504666A1 (en) 2004-05-27
KR20050074573A (ko) 2005-07-18
US20060142297A1 (en) 2006-06-29
CN1711094A (zh) 2005-12-21
ATE456370T1 (de) 2010-02-15
EP1562612B1 (en) 2010-01-27
AU2003279456A1 (en) 2004-06-03
JP2006508953A (ja) 2006-03-16
NZ539514A (en) 2007-11-30

Similar Documents

Publication Publication Date Title
EP1562612B1 (en) Combination product of inhibitor of the src family of non-receptor tyrosine kinases and gemcitabine for use in the treatment or prophlaxix of pancreatic cancer
ES2225545T3 (es) Derivados de quinazolina para el tratamiento de tumores.
CN113966335B (zh) 用于治疗癌症的egfr抑制剂
US20100029673A1 (en) Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use
RU2267489C2 (ru) Производные хиназолина, способ их получения и фармацевтическая композиция
CN103596948B (zh) 用于治疗癌症的作为pi3-激酶抑制剂的苯并吡喃酮化合物
ES2312557T3 (es) Derivados de quinazolina.
US20110086870A1 (en) Combination Therapy
ES2272737T3 (es) Derivados de quinolina y su uso como inhibidores de tirosina quinasas.
HK1204575A1 (en) Combinations of akt inhibitor compounds and abiraterone, and methods of use
PT1446124E (pt) Terapia de combinação compreendendo zd6474 e um taxano
JP2009533472A (ja) 癌治療法
US20070207996A1 (en) Novel Compositions And Methods Of Treatment
US20090221488A1 (en) Certain Compositions and Methods of Treatment
MXPA06013635A (es) Metodo para el tratamiento de cancer.
MXPA05005119A (es) Producto de combinacion de inhibidor de la familia src de cinasas de tirosina de no receptor y gemcitabina.
CN111253314B (zh) 乙烯基磺酰胺基取代的吡唑基苯甲酰胺类化合物
CN111718328A (zh) 4-甲基-1h-二芳基吡唑类衍生物在制备抗肿瘤药物中的用途
CN111777621B (zh) 喹唑啉衍生物类酪氨酸激酶抑制剂的新用途
KR20250099146A (ko) Prmt5 저해제와 dna 손상 유도 물질의 약학적 조합물
TWI307628B (en) Use of zd0473 in combination with a non-platinum based anti-cancer agent
WO2018106118A1 (en) Treatment of diffuse intrinsic pontine glioma
JP2014034533A (ja) Ｈｓｐ９０阻害剤とｅｇｆｒチロシンキナーゼ阻害剤の組み合わせ